Sha Hao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sha Hao has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
- Tao Cheng
Institute of Hematology and Blood Diseases Hospital
13 shared publications Fang Dong
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
6 shared publicationsShihui Ma
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
6 shared publicationsWeiqian Dai
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
4 shared publicationsAiming Pang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
3 shared publications- Erlie Jiang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 shared publications
Latest Publications
- 12 October 2026
- Published by Springer Nature in Science China Life Sciences
- p. 1-14
Current understanding and new promises of umbilical cord blood in emerging clinical applications
- 12 October 2026
- Published by Springer Nature in Science China Life Sciences
- p. 1-14
Current understanding and new promises of umbilical cord blood in emerging clinical applications
- Open Access
- 7 October 2026
- Published by Springer Nature in Biomarker Research
- Vol. 14 (1) , 132
Monocyte Galectin-9 is associated with CD8⁺ T-cell dysfunction and early relapse after haploidentical hematopoietic stem cell transplantation
- 7 October 2026
- Published by Springer Nature in Biomarker Research
- Vol. 14 (1) , 132
Open AccessMonocyte Galectin-9 is associated with CD8⁺ T-cell dysfunction and early relapse after haploidentical hematopoietic stem cell transplantation
- Open Access
- 2 March 2026
- Published by Wolters Kluwer Health in Blood Science
- Vol. 8 (1) , e00283
Deciphering the blueprint of life: integrated protocols for single-cell multi-omics and functional genomics
- 2 March 2026
- Published by Wolters Kluwer Health in Blood Science
- Vol. 8 (1) , e00283
Open AccessDeciphering the blueprint of life: integrated protocols for single-cell multi-omics and functional genomics
- Open Access
- 1 December 2025
- Published by Wolters Kluwer Health in Blood Science
- Vol. 7 (4) , e00261
T Cell immune reconstitution after allo-HSCT: key factors and implications
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents a curative therapy for hematological malignancies, with T-cell immune reconstitution playing a pivotal role in determining clinical outcomes. This review comprehensively illustrates the processes and influencing factors of T-cell recovery post-HSCT, highlighting the dual pathways of reconstitution: thymus-independent peripheral expansion and thymus-dependent central regeneration. Key factors such as recipient and donor age, human leukocyte antigen disparity, conditioning regimens, immunosuppressive therapies, cytomegalovirus reactivation, and graft-versus-host disease (GVHD) significantly impact T-cell reconstitution dynamics and functional recovery. Furthermore, the article discusses the critical balance between graft-versus-leukemia (GVL) effects and GVHD, emphasizing how T-cell exhaustion, inhibitory receptor overexpression, and clonal dynamics contribute to relapse. Emerging technologies, including single-cell multi-omics, spatially resolved proteomics, T cell receptor repertoire analysis, and artificial intelligence-driven modeling, are explored for their potential to deepen mechanistic understanding and enable personalized therapeutic strategies. Ultimately, enhancing T-cell reconstitution through optimized transplantation protocols and targeted interventions is essential for reducing complications and improving long-term survival.
- 1 December 2025
- Published by Wolters Kluwer Health in Blood Science
- Vol. 7 (4) , e00261
Open AccessT Cell immune reconstitution after allo-HSCT: key factors and implications
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents a curative therapy for hematological malignancies, with T-cell immune reconstitution playing a pivotal role in determining clinical outcomes. This review comprehensively illustrates the processes and influencing factors of T-cell recovery post-HSCT, highlighting the dual pathways of reconstitution: thymus-independent peripheral expansion and thymus-dependent central regeneration. Key factors such as recipient and donor age, human leukocyte antigen disparity, conditioning regimens, immunosuppressive therapies, cytomegalovirus reactivation, and graft-versus-host disease (GVHD) significantly impact T-cell reconstitution dynamics and functional recovery. Furthermore, the article discusses the critical balance between graft-versus-leukemia (GVL) effects and GVHD, emphasizing how T-cell exhaustion, inhibitory receptor overexpression, and clonal dynamics contribute to relapse. Emerging technologies, including single-cell multi-omics, spatially resolved proteomics, T cell receptor repertoire analysis, and artificial intelligence-driven modeling, are explored for their potential to deepen mechanistic understanding and enable personalized therapeutic strategies. Ultimately, enhancing T-cell reconstitution through optimized transplantation protocols and targeted interventions is essential for reducing complications and improving long-term survival.
- 19 November 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (825) , eadu0114
Targeting the origins of multiple myeloma along hematopoietic stem cell lymphoid lineage differentiation
The initiation and progression of multiple myeloma (MM) are intricate processes, and a critical challenge lies in understanding the mechanisms of malignant transformation in MM-initiating cells (MICs) and their driver genes. In this study, we used single-cell sequencing and genetic tracer analysis at each developmental stage, from hematopoietic stem cells to lymphoid lineage differentiation, to identify abnormal differentiation stages in patients with MM. We found that chromosome 1q amplification (1q Amp ) originated from a specific subgroup of B cells, whereas chromosome 17p deletion occurred at the plasma cell stage. 1q Amp was present in CD24 − FCRL5 + B cell subgroups and initiated B cell transformation into malignant plasma cells by enhancing B cell proliferation and promoting plasma cell differentiation in vitro and in vivo. FCRL5 facilitated B cell differentiation into malignant plasma cells through its interaction with the IRF4/SPI1 complex. The use of targeted FCRL5 CAR T cells in patients with relapsed or refractory MM (RRMM) showed promising safety and efficacy. Together, our work identified genetic events linked to the initiation and malignant transformation of MM along the B cell lineage. These findings form the foundation for identifying potential therapeutic strategies for patients with RRMM by targeting MICs and their driving oncogenes.
- 19 November 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (825) , eadu0114
Targeting the origins of multiple myeloma along hematopoietic stem cell lymphoid lineage differentiation
The initiation and progression of multiple myeloma (MM) are intricate processes, and a critical challenge lies in understanding the mechanisms of malignant transformation in MM-initiating cells (MICs) and their driver genes. In this study, we used single-cell sequencing and genetic tracer analysis at each developmental stage, from hematopoietic stem cells to lymphoid lineage differentiation, to identify abnormal differentiation stages in patients with MM. We found that chromosome 1q amplification (1q Amp ) originated from a specific subgroup of B cells, whereas chromosome 17p deletion occurred at the plasma cell stage. 1q Amp was present in CD24 − FCRL5 + B cell subgroups and initiated B cell transformation into malignant plasma cells by enhancing B cell proliferation and promoting plasma cell differentiation in vitro and in vivo. FCRL5 facilitated B cell differentiation into malignant plasma cells through its interaction with the IRF4/SPI1 complex. The use of targeted FCRL5 CAR T cells in patients with relapsed or refractory MM (RRMM) showed promising safety and efficacy. Together, our work identified genetic events linked to the initiation and malignant transformation of MM along the B cell lineage. These findings form the foundation for identifying potential therapeutic strategies for patients with RRMM by targeting MICs and their driving oncogenes.
- 22 August 2025
- Published by MyJove Corporation
- No. 222,p. e68904
JoVE Video Dataset
Xenogeneic cell transplantation often faces significant immune rejection, even in immunodeficient animal models. Among residual immune components, macrophages can actively phagocytose transplanted human cells, posing a challenge to long-term engraftment. To address this, we developed a standardized in vitro assay to quantify macrophage-mediated phagocytosis of human versus rat red blood cells (RBCs). Rat peritoneal macrophages were isolated, cultured, and exposed to either human or rat RBCs. Human RBCs were identified using CD235a, while rat RBCs were pre-labeled with DeepRed. Flow cytometry analysis was conducted using CD163 to identify macrophages and propidium iodine (PI) exclusion to gate living cells. The results showed a substantial difference in phagocytic activity: 5.08% of macrophages engulfed human RBCs, while only 1.59% phagocytosed rat RBCs, yielding a relative phagocytosis index of 3.21. This protocol allows for quantitative assessment of immune compatibility and offers a reproducible method to evaluate innate immune responses in xenotransplantation. It holds potential for refining donor-recipient selection and guiding immunosuppressive strategies in translational research.
- 22 August 2025
- Published by MyJove Corporation
- No. 222,p. e68904
JoVE Video Dataset
Xenogeneic cell transplantation often faces significant immune rejection, even in immunodeficient animal models. Among residual immune components, macrophages can actively phagocytose transplanted human cells, posing a challenge to long-term engraftment. To address this, we developed a standardized in vitro assay to quantify macrophage-mediated phagocytosis of human versus rat red blood cells (RBCs). Rat peritoneal macrophages were isolated, cultured, and exposed to either human or rat RBCs. Human RBCs were identified using CD235a, while rat RBCs were pre-labeled with DeepRed. Flow cytometry analysis was conducted using CD163 to identify macrophages and propidium iodine (PI) exclusion to gate living cells. The results showed a substantial difference in phagocytic activity: 5.08% of macrophages engulfed human RBCs, while only 1.59% phagocytosed rat RBCs, yielding a relative phagocytosis index of 3.21. This protocol allows for quantitative assessment of immune compatibility and offers a reproducible method to evaluate innate immune responses in xenotransplantation. It holds potential for refining donor-recipient selection and guiding immunosuppressive strategies in translational research.
- 22 August 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 222,p. e68904
A Quantitative Assessment of the Phagocytosis of Allogeneic and Xenogeneic Erythrocytes by Rat Macrophages In Vitro
Xenogeneic cell transplantation often faces significant immune rejection, even in immunodeficient animal models. Among residual immune components, macrophages can actively phagocytose transplanted human cells, posing a challenge to long-term engraftment. To address this, we developed a standardized in vitro assay to quantify macrophage-mediated phagocytosis of human versus rat red blood cells (RBCs). Rat peritoneal macrophages were isolated, cultured, and exposed to either human or rat RBCs. Human RBCs were identified using CD235a, while rat RBCs were pre-labeled with DeepRed. Flow cytometry analysis was conducted using CD163 to identify macrophages and propidium iodine (PI) exclusion to gate living cells. The results showed a substantial difference in phagocytic activity: 5.08% of macrophages engulfed human RBCs, while only 1.59% phagocytosed rat RBCs, yielding a relative phagocytosis index of 3.21. This protocol allows for quantitative assessment of immune compatibility and offers a reproducible method to evaluate innate immune responses in xenotransplantation. It holds potential for refining donor-recipient selection and guiding immunosuppressive strategies in translational research.
- 22 August 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 222,p. e68904
A Quantitative Assessment of the Phagocytosis of Allogeneic and Xenogeneic Erythrocytes by Rat Macrophages In Vitro
Xenogeneic cell transplantation often faces significant immune rejection, even in immunodeficient animal models. Among residual immune components, macrophages can actively phagocytose transplanted human cells, posing a challenge to long-term engraftment. To address this, we developed a standardized in vitro assay to quantify macrophage-mediated phagocytosis of human versus rat red blood cells (RBCs). Rat peritoneal macrophages were isolated, cultured, and exposed to either human or rat RBCs. Human RBCs were identified using CD235a, while rat RBCs were pre-labeled with DeepRed. Flow cytometry analysis was conducted using CD163 to identify macrophages and propidium iodine (PI) exclusion to gate living cells. The results showed a substantial difference in phagocytic activity: 5.08% of macrophages engulfed human RBCs, while only 1.59% phagocytosed rat RBCs, yielding a relative phagocytosis index of 3.21. This protocol allows for quantitative assessment of immune compatibility and offers a reproducible method to evaluate innate immune responses in xenotransplantation. It holds potential for refining donor-recipient selection and guiding immunosuppressive strategies in translational research.
- Open Access
- 1 July 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 1-15
Deletion of p18INK4c enhances both osteogenesis and hematopoietic supportive capacity of bone marrow mesenchymal stromal cells
P18INK4 C (CDKN2C, encoded by p18INK4c or Cdkn2c) is an early G1-phase cyclin-dependent kinase inhibitor protein. Previous studies demonstrated enhanced self-renewal capacity of hematopoietic stem cells (HSCs) in p18−/− mice compared to wild-type (WT) mice. Given the critical role of bone marrow niche cells-particularly mesenchymal stromal cells (MSCs)-in hematopoiesis, this study investigated the functional alterations of p18−/− MSCs and their impact on hematopoietic support. Bone marrow derived MSCs were isolated from p18−/− and WT mice. Their proliferation and differentiation capacities were assessed, followed by evaluation of hematopoietic support using cobblestone area-forming cell assay and long-term culture-initiating cell assay. RNA sequencing was performed to analyze the transcriptional profile of p18−/− MSCs, with a focus on differentially expressed genes (DEGs). Key pathways associated with hematopoietic support were identified using Ingenuity Pathway Analysis. A candidate protein was quantified by ELISA, and its functional role in hematopoietic support was validated via a modified coculture system. p18−/− MSCs displayed an increased proliferation rate, preferential differentiation toward osteogenesis over adipogenesis, and enhanced hematopoietic support. RNA sequencing analysis identified 137 DEGs, with secreted phosphoprotein 1 (Spp1, encoding osteopontin, Opn) being significantly upregulated in p18−/− MSCs. Elevated Opn levels were confirmed in both bone marrow and MSC-conditioned media from p18−/− mice. Functional validation further demonstrated that Opn enhanced the hematopoietic supportive capacity of MSCs in vitro. p18 deficiency promotes osteogenic differentiation and enhances the hematopoietic supportive function of MSCs, likely mediated by Opn upregulation. These findings suggest a potential therapeutic strategy for improving bone regeneration and HSC expansion.
- 1 July 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 1-15
Open AccessDeletion of p18INK4c enhances both osteogenesis and hematopoietic supportive capacity of bone marrow mesenchymal stromal cells
P18INK4 C (CDKN2C, encoded by p18INK4c or Cdkn2c) is an early G1-phase cyclin-dependent kinase inhibitor protein. Previous studies demonstrated enhanced self-renewal capacity of hematopoietic stem cells (HSCs) in p18−/− mice compared to wild-type (WT) mice. Given the critical role of bone marrow niche cells-particularly mesenchymal stromal cells (MSCs)-in hematopoiesis, this study investigated the functional alterations of p18−/− MSCs and their impact on hematopoietic support. Bone marrow derived MSCs were isolated from p18−/− and WT mice. Their proliferation and differentiation capacities were assessed, followed by evaluation of hematopoietic support using cobblestone area-forming cell assay and long-term culture-initiating cell assay. RNA sequencing was performed to analyze the transcriptional profile of p18−/− MSCs, with a focus on differentially expressed genes (DEGs). Key pathways associated with hematopoietic support were identified using Ingenuity Pathway Analysis. A candidate protein was quantified by ELISA, and its functional role in hematopoietic support was validated via a modified coculture system. p18−/− MSCs displayed an increased proliferation rate, preferential differentiation toward osteogenesis over adipogenesis, and enhanced hematopoietic support. RNA sequencing analysis identified 137 DEGs, with secreted phosphoprotein 1 (Spp1, encoding osteopontin, Opn) being significantly upregulated in p18−/− MSCs. Elevated Opn levels were confirmed in both bone marrow and MSC-conditioned media from p18−/− mice. Functional validation further demonstrated that Opn enhanced the hematopoietic supportive capacity of MSCs in vitro. p18 deficiency promotes osteogenic differentiation and enhances the hematopoietic supportive function of MSCs, likely mediated by Opn upregulation. These findings suggest a potential therapeutic strategy for improving bone regeneration and HSC expansion.